Defining an Individualized Treatment Strategy for Metastatic Renal Cancer
Defining an Individualized Treatment Strategy for Metastatic Renal Cancer
复制标题
DOI：
10.1016/j.ucl.2012.02.002
复制
发表时间：
2012-05-01
影响因子：
2.4
通讯作者：
Evans, Christopher P.
中科院分区：
文献类型：
--
作者：
Hu, Brian;Lara, Primo N., Jr.;Evans, Christopher P.
转移性肾细胞癌（mRCC）的治疗在过去10年里发生了巨大的变化，以血管生成和哺乳动物雷帕霉素（mTOR）途径为靶点的治疗方法的出现。这些疗法迅速取代免疫疗法，成为一线全身治疗的选择。然而，缓解率继续变化，主要是由于mRCC的临床和分子异质性。本文回顾了目前对nnRCC生物学和现有治疗方法的认识，讨论了改善预后和可能预测反应的新型生物标志物，并将现有的外科和全身治疗文献整合为个体化治疗策略。
Treatment of metastatic renal cell carcinoma (mRCC) has evolved dramatically within the past 10 years with the advent of therapy targeting the angiogenesis and mammalian target of rapamycin (mTOR) pathways. These therapies rapidly supplanted immunotherapy as a first-line systemic treatment option. Response rates, however, continue to vary, largely due to mRCC's clinical and molecular heterogeneity. This article reviews current understanding of nnRCC biology and available treatments, discusses novel biomarkers that improve prognostication and may be able to predict response, and integrates available literature on surgical and systemic therapies into an individualized strategy.